ABVC BioPharma, Inc. Overview

Company Profile

• Incorporation: February 6, 2002, under the laws of Nevada.
• Headquarters: Fremont, CA.
• Number of Employees: 19 (16 full-time) as of December 31, 2024.
• Stock Symbol: ABVC, listed on The Nasdaq Capital Market.

Business Focus

ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company primarily focused on the development of innovative therapeutic products, particularly botanical drugs. The company's pipeline includes seven drug candidates and one medical device, all designed for various medical conditions, particularly in the fields of central nervous system (CNS) disorders and oncology/hematology.

Pipeline Overview

1. Drug Candidates:
   • ABV-1504: Treatment for Major Depressive Disorder (MDD).
   • ABV-1505: Treatment for Attention-Deficit Hyperactivity Disorder (ADHD).
   • ABV-1601: Treatment for depression in cancer patients.
   • ABV-1519: Treatment for Non-Small Cell Lung Cancer.
   • ABV-1702: Treatment for Myelodysplastic Syndromes.
   • ABV-1703: Treatment for Pancreatic Cancer.
   • ABV-1501: Combination therapy for Triple Negative Breast Cancer.
2. Medical Device:
   • ABV-1701: Vitargus®, a vitreous substitute for use in vitrectomy surgery.

Business Model

• Revenue Generation:
  • The company primarily generates revenue through:
    • Out-licensing of intellectual property.
    • Contract Development and Manufacturing Organization (CDMO) services.
  • Revenue for the year ended December 31, 2024, amounted to $509,589.

Customer Base

• As of April 11, 2025, the company had approximately 656 shareholders of record.
• The revenue derived from CDMO services and out-licensing is based on collaborations with major pharmaceutical companies and other entities.

Financial Condition

• Current Liabilities: Approximately $6.6 million as of December 31, 2024, including short-term bank loans and accrued expenses.
• Total Assets: Approximately $7.78 million as of December 31, 2023 (restated figures).
• Stockholders' Equity: Approximately $1.25 million after restatement.
• Net Revenue: Was primarily generated from CDMO services and out-licensing activities.

Key Financial Metrics

• Total Revenue:
  • 2023: Approximately $509,589.
  • The company has never paid dividends and does not anticipate paying dividends in the foreseeable future.
  • Net Loss: Reported as $8.28 million for the year ended December 31, 2023 (restated).

Operational Highlights

• Collaborative Agreements: Engaged in various collaborative agreements with partners, including BioHopeKing and Rgene Corporation.
• Clinical Trials: Ongoing clinical trials for several products, including Phase II trials for ABV-1504, ABV-1505, and ABV-1701.
• Regulatory Compliance: The company needs to navigate a complex regulatory landscape and demonstrate the safety and efficacy of its drug candidates to obtain FDA approval.

Summary

ABVC BioPharma, Inc. is an early-stage biopharmaceutical company with a focus on botanical drug development targeting significant unmet medical needs. With a diverse pipeline and strategic agreements, the company aims to cooperate with larger pharmaceutical entities for commercialization while managing financial and operational challenges inherent in the biopharmaceutical landscape.